Last updated on July 2019

Study of Single Agent CJM112 and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Brief description of study

The purpose of this study is to assess the safety, tolerability, and identify the recommended doses of single agent CJM112, and of CJM112 or LCL161 in combination with PDR001, in patients with relapsed and/or refractory multiple myeloma.

Clinical Study Identifier: NCT03111992

Find a site near you

Start Over

Novartis Investigative Site

Heidelberg, Germany
  Connect »